Abstract
The fluoroquinolones (FQs) have proven to be successful for treating ocular infections because the introduction of ciprofloxacin and ofloxacin; the improvement in ofloxacin to levofloxacin, the active l-isomer of ofloxacin; and the targeting of Gram-positive bacteria by moxifloxacin and gatifloxacin with a dual mechanism of action. The in vitro testing of the FQs has determined that moxifloxacin and gatifloxacin are more potent anti-infectives with lower minimum inhibitory concentrations (MICs) to Gram-positive bacteria than the earlier generations of FQs, but no real advantage for in vitro susceptibility has been noted among the FQs for Gram-negative bacteria. The objective of this review is to outline the pharmacogenetics, pharmacokinetics, and efficacy of levofloxacin along with the impact on patients’ life. Such particular approach, being the foundation of personalized medicine, increases efficacy and safety of timolol while reducing costs by using targeted doses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
